Showing 631-640 of 7438 results for "".
Cognitive Bias And The Art of Doctoring
https://practicaldermatology.com/topics/practice-management/cognitive-bias-and-the-art-of-doctoring/23680/Rethinking the approach to diagnosis may reduce errors and improve patient interactions.How Artificial Intelligence and Chatbots are Enhancing Medical Experiences for Patients
https://practicaldermatology.com/topics/practice-management/how-artificial-intelligence-and-chatbots-are-enhancing-medical-experiences-for-patients/23570/Medical practices are leveraging technology to increase patient care and overall efficiencies to improve the all-around customer experience.Advances in PsO: Targeting IL-23
https://practicaldermatology.com/conferences/aad-summer-2021/advances-in-pso-targeting-il-23/19974/George Han, MD, PhD reviews the latest data available on IL-23 inhibitors for the treatment of psoriasis. He discusses the specific benefits of guselkumab, tildrakizumab, and risankizumab and shares insights about how they fit into the overall psoriasis treatment arsenal.DermWireTV: Sanofi Genzyme & Regeneron Global AD Report; Hydroquinone; Pfizer NDA; VCS
https://practicaldermatology.com/topics/practice-management/dermwiretv-sanofi-genzyme-regeneron-global-ad-report-hydroquinone-pfizer-nda-vcs/19868/The “Improving Quality of Care in AD” report, commissioned and funded by Sanofi Genzyme & Regeneron and completed by KPMG, debuts at the annual meeting of the EADV. Changes to FDA regulations implemented as part of the CARES Act limit access to hydroquinone. This year’s Virtual Vegas Cosmetic SuBuyer Beware: CBD Products May Peddle False Hope Amid Corona Fears
https://practicaldermatology.com/series/dermatology-dispatches/buyer-beware-cbd-products-may-peddle-false-hope-amid-corona-fears/19775/Any claims that a medical cannabinoid-based product can kill COVID-19 are “absolutely unsubstantiated,” warns Adam Friedman, MD. There is no evidence that these products contain any antiviral properties, and patients should be advised against believing such claims.Advances in Tattoo Removal and More
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/advances-in-tattoo-removal-and-more/19756/Eric Bernstein, MD shares insights on the benefits of picosecond domain lasers for everything from rejuvenation to tattoo removal. He discusses his recent experience with the 730nm handpiece and its efficacy on multiple ink colors and all skin types. In addition, he talks about other new technologieTaking “picture perfect” before and after photos
https://practicaldermatology.com/topics/practice-management/taking-picture-perfect-before-and-after-photos/19751/You probably know the importance of including before and after photos on your dermatology website. However, you might be wondering how to create a professional looking image gallery without a photographer on call. Check out the latest video from Ekwa Marketing to find out!DermWireTV: Latest on Galderma, Eczema Awareness, Hacking Derm, and More
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-latest-on-galderma-eczema-awareness-hacking-derm-and-more/19675/In this week’s edition: Galderma’s Aklief (trifarotene) topical cream is now approved for acne. Sandra Johnson, MD weighs in. Supported by Sanofi and Regeneron in partnership with the National Eczema Association, the Understand AD Squad includes dermatologist Mercedes Gonzalez, MD, who discusses her10 Things Dermatologists Need to Know About Treating Vitiligo Today
https://practicaldermatology.com/topics/pigmentary-disorders/10-things-dermatologists-need-to-know-about-treating-vitiligo-today/22988/New and emerging treatment approaches offer hope for this challenging condition.Galderma's Future, Allergan's Bonti Buy, and Sebacia Clearance
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-galderma-s-future-allergan-s-bonti-buy-and-sebacia-clearance--xgheloga/18233/Nestle's Board says it has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group's strategic scope and expects a review of strategic options for Nestlé Skin Health to be complete by mid-2019. Allergan is acquiring Bonti for 195 million d